PALISADE BIO, INC.

PALI

PALISADE BIO, INC.

PALI

Insider Sentiment (TTM):

Last Purchase:2026-01-16Last Sale:2026-02-12Shares Purchased (TTM):10,000Shares Sold (TTM):5,885

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:146,423,217Shares Outstanding:209,663,966Institutional Ownership Pct.:69.84%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets Current
Cash And Cash Equivalents At Carrying Value	125	133	133	5	5	7	10	8	11	11	12	15
Prepaid Expense And Other Assets Current	2	1	1	2	1	1	1	1	1	1	1	1
Assets Current	127	133	134	7	6	8	10	9	12	12	13	16
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	-	-	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	-	-	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	1
Assets	127	133	134	7	7	8	11	9	13	13	14	17
Liabilities Current
Accounts Payable Current	2	3	1	1	1	1	1	0	1	0	1	1
Accrued Liabilities Current	3	3	2	1	2	2	1	2	2	2	1	1
Employee Related Liabilities Current	0	0	1	1	0	0	1	0	0	0	1	1
Operating Lease Liability Current	-	-	0	0	0	0	0	0	0	0	0	0
Accrued Insurance Current	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities Current	5	6	5	3	4	3	3	3	3	2	3	3
Derivative Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Other Liabilities Noncurrent	-	-	-	0	-	-	-	-	-	-	-	-
Business Combination Contingent Consideration Liab…	0	0	0	-	0	0	0	0	0	0	0	0
Liabilities	6	6	5	4	4	3	3	3	3	3	3	3
Stockholders Equity
Common Stock Value	2	2	2	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	293	288	281	147	144	143	143	139	139	135	133	133
Stockholders Equity	122	127	129	3	3	5	7	7	10	10	11	14
Liabilities And Stockholders Equity	127	133	134	7	7	8	11	9	13	13	14	17
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	450	300	300	280	280	280	280	280	280	280	280	280
Common Stock Shares Issued	174	167	159	9	5	4	3	1	1	1	1	1
Shares Outstanding	174	167	159	9	5	4	3	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-9.37%	9.37%	-1.04%	-	-	-	-	-	-	-	-	-
2025	-9.09%	-5.19%	31.17%	-14.86%	116.22%	179.73%	1.69%	41.24%	-15.82%	-3.70%	-4.76%	-7.94%
2024	-26.53%	-27.81%	-41.00%	-1.91%	-6.28%	-24.32%	-25.63%	-20.17%	-42.86%	2.86%	-1.43%	-8.57%
2023	-	-	-	-	-	-	17.31%	13.46%	0.00%	-15.14%	14.59%	-16.40%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	24.26	23.71	28.95	1.96	1.62	2.84	3.24	3.31	4.34	4.87	5.15	6.14
Quick Ratio	23.96	23.60	28.77	1.50	1.36	2.60	3.03	3.00	4.00	4.57	4.81	5.78
Working Capital	122.01M	127.62M	129.59M	3.35M	2.48M	5.11M	7.26M	6.19M	9.48M	9.55M	10.74M	13.62M
Leverage & Debt
Debt to Equity	0.05	0.05	0.04	1.17	1.54	0.54	0.45	0.41	0.29	0.26	0.24	0.21
Interest Coverage TTM	-5,891.50	-3,311.75	-2,257.00	-1,041.55	-1,010.67	-1,124.67	-1,238.25	-1,125.46	-987.73	-888.38	-871.33	-983.14
Debt Ratio	0.04	0.04	0.04	0.54	0.61	0.35	0.31	0.29	0.23	0.20	0.19	0.17
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
Per Share Metrics
Diluted EPS TTM	-0.15	-0.12	-0.30	-1.50	-2.47	-2.74	-10.19	-9.36	-11.54	-17.56	-26.97	-26.68
Free Cash Flow Per Share TTM	-0.09	-0.06	-0.19	-1.35	-2.01	-2.37	-8.61	-8.37	-9.84	-14.05	-24.42	-23.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-5,228.00%	-5,505.60%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-4,920.00%	-5,226.00%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-	-
Net Income Growth (1Y)	169.66%	83.78%	16.23%	-20.09%	-16.43%	-2.57%	17.38%	7.53%	5.43%	8.81%	-13.74%	38.01%
EPS Growth (1Y)	-93.88%	-95.80%	-97.04%	-83.96%	-78.60%	-84.39%	-62.21%	-64.91%	-63.28%	-59.25%	-88.89%	-81.68%
Valuation Metrics
P/E TTM	-13.83	-15.19	-7.80	-0.57	-0.28	-0.25	-0.16	-0.38	-0.39	-0.34	-0.33	-0.33
P/B TTM	3.63	2.88	1.01	2.00	1.25	0.61	0.31	0.81	0.56	0.46	0.36	0.30
P/S TTM	-	-	-	-	-	-	-	-	-	-	16.14	17.04
Market Cap	441.79M	366.91M	130.82M	6.43M	3.26M	3.26M	2.34M	5.33M	5.53M	4.61M	4.04M	4.26M
Enterprise Value	316.62M	234.28M	15.31M	1.20M	-2.15M	-3.97M	-7.48M	-2.71M	-5.82M	-6.67M	-8.40M	-11.05M
Calculated Values
Free Cash Flow TTM	-18.19M	-12.40M	-10.85M	-10.08M	-9.66M	-11.35M	-12.19M	-12.56M	-12.09M	-10.79M	-11.14M	-11.71M
Net Debt	-125.17M	-132.63M	-115.51M	-5.23M	-5.42M	-7.23M	-9.82M	-8.04M	-11.35M	-11.28M	-12.43M	-15.31M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-12Sale

Owner: Jones, Mitchell Lawrence

Title: Chief Medical Officer

Shares: 1,989

Price/Share: $1.75

Value: $3,480.75

Shares Owned: 13,263

Relationship: Officer

Ownership: Direct

2026-02-12Sale

Owner: Finley, John David

Title: CEO, CFO

Shares: 3,896

Price/Share: $1.75

Value: $6,818.00

Shares Owned: 27,353

Relationship: Director,Officer

Ownership: Direct

2026-01-16Purchase

Owner: Williams, Donald Allen

Title: -

Shares: 5,000

Price/Share: $1.67

Value: $8,350.00

Shares Owned: 10,728

Relationship: Director

Ownership: Direct

2026-01-09Purchase

Owner: Williams, Donald Allen

Title: -

Shares: 5,000

Price/Share: $1.88

Value: $9,400.00

Shares Owned: 5,728

Relationship: Director

Ownership: Direct

2024-05-28Purchase

Owner: Williams, Donald Allen

Title: -

Shares: 1,000

Price/Share: $4.86

Value: $4,860.00

Shares Owned: 1,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-12	Jones, Mitchell Lawrence	Officer	Chief Medical Officer	Direct	Sale	1,989	1.75	$3,480.75	13,263	4
2026-02-12	Finley, John David	Director,Officer	CEO, CFO	Direct	Sale	3,896	1.75	$6,818.00	27,353	4
2026-01-16	Williams, Donald Allen	Director	-	Direct	Purchase	5,000	1.67	$8,350.00	10,728	4
2026-01-09	Williams, Donald Allen	Director	-	Direct	Purchase	5,000	1.88	$9,400.00	5,728	4
2024-05-28	Williams, Donald Allen	Director	-	Direct	Purchase	1,000	4.86	$4,860.00	1,000	4
2024-05-24	Finley, John David	Director,Officer	CEO, CFO, Director	Direct	Purchase	1,000	4.81	$4,810.00	8,437	4
2024-02-06	Finley, John David	Director,Officer	CEO, CFO, Director	Direct	Purchase	10,000	0.47	$4,700.00	84,649	4
2024-01-31	Williams, Donald Allen	Director	-	Indirect	Purchase	10,000	0.61	$6,100.00	30,000	4
2024-01-31	Finley, John David	Director,Officer	CEO, CFO, Director	Direct	Purchase	10,000	0.56	$5,600.00	74,649	4
2023-09-27	Finley, John David	Director,Officer	CEO, CFO, Director	Direct	Purchase	15,000	0.54	$8,100.00	43,394	4
2023-09-27	Williams, Donald Allen	Director	-	Indirect	Purchase	20,000	0.54	$10,800.00	20,000	4
2023-09-14	Trenschel, Robert J.	Director	-	Direct	Sale	300	0.64	$192.00	0	4
2023-09-13	Finley, John David	Director,Officer	CEO, CFO, Director	Direct	Purchase	15,000	0.66	$9,900.00	28,394	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

69.84%

Inst. Shares: 146,423,217

Shares Outstanding: 209,663,966

2025-12-31

241.19%

Inst. Shares: 134,271,335

Shares Outstanding: 55,669,821

2025-09-30

1.60%

Inst. Shares: 119,592

Shares Outstanding: 7,473,898

2025-06-30

1.76%

Inst. Shares: 84,610

Shares Outstanding: 4,797,196

2025-03-31

4.74%

Inst. Shares: 227,107

Shares Outstanding: 4,795,646

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	146,423,217	209,663,966	69.84%
2025-12-31	134,271,335	55,669,821	241.19%
2025-09-30	119,592	7,473,898	1.60%
2025-06-30	84,610	4,797,196	1.76%
2025-03-31	227,107	4,795,646	4.74%
2024-12-31	199,223	1,416,471	14.06%
2024-09-30	62,098	1,500,409	4.14%
2024-06-30	30,078	1,228,453	2.45%
2024-03-31	897,998	768,137	116.91%
2023-12-31	160,083	456,014	35.10%
2023-09-30	148,432	489,624	30.32%
2023-06-30	133,030	427,862	31.09%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

PALISADE BIO, INC. (PALI) — SEC Financial Statements & Analysis

PALISADE BIO, INC. (PALI) is a biological products, (no diagnostic substances) company, incorporated in DE. PALISADE BIO, INC. trades on Nasdaq as: PALI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), PALISADE BIO, INC. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.05x, a Price-to-Sales (P/S) ratio of 16.14x (TTM), a Price-to-Book (P/B) ratio of 3.63x (TTM), at a market cap of $441.79M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.05x
P/S TTM: 16.14x
P/B TTM: 3.63x
Market Cap: $441.79M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is PALISADE BIO, INC. in?

PALISADE BIO, INC. (PALI) operates in the Biological Products, (No Diagnostic Substances) industry.

What is PALI's market cap?

PALISADE BIO, INC. (PALI) has a market capitalization of $441.79M as of 2026-06-30.

What exchange does PALI trade on?

PALISADE BIO, INC. (PALI) trades on the Nasdaq.

Where is PALISADE BIO, INC. incorporated?

PALISADE BIO, INC. is incorporated in DE.

PALISADE BIO, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

PALISADE BIO, INC. (PALI) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

PALISADE BIO, INC. (PALI) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.